Joseph M Connors
Overview
Explore the profile of Joseph M Connors including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
302
Citations
25807
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim J, Gerrie A, Savage K, Villa D, Scott D, Craig J, et al.
Leuk Lymphoma
. 2023 Dec;
65(3):346-352.
PMID: 38156444
We report on outcomes of 111 patients with treatment naïve Waldenström macroglobulinemia (TN WM) treated with frontline bendamustine-rituximab (BR) ( = 57) or rituximab-cyclophosphamide-vincristine-prednisone (RCVP) ( = 54). Median follow-up...
2.
Khelifi R, Huang S, Savage K, Villa D, Scott D, Ramadan K, et al.
Leuk Lymphoma
. 2023 Apr;
64(6):1129-1138.
PMID: 37086469
Ibrutinib has dramatically changed the treatment landscape for chronic lymphocytic leukemia (CLL) since its availability in British Columbia (BC), Canada in 2014. We analyzed patterns of use and real-world survival...
3.
Dreval K, Hilton L, Cruz M, Shaalan H, Ben-Neriah S, Boyle M, et al.
Blood
. 2023 Apr;
142(6):561-573.
PMID: 37084389
Follicular lymphoma (FL) accounts for ∼20% of all new lymphoma cases. Increases in cytological grade are a feature of the clinical progression of this malignancy, and eventual histologic transformation (HT)...
4.
Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population
Alduaij W, Collinge B, Ben-Neriah S, Jiang A, Hilton L, Boyle M, et al.
Blood
. 2022 Oct;
141(20):2493-2507.
PMID: 36302166
Molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) underlies the variable outcomes achieved with immunochemotherapy. However, outcomes of gene expression profiling (GEP)-defined molecular subgroups in a real-world DLBCL population remain...
5.
Cheng P, Villa D, Gerrie A, Freeman C, Slack G, Gascoyne R, et al.
Blood Adv
. 2022 Sep;
6(22):5924-5932.
PMID: 36075016
Outcomes in older adults with classic Hodgkin lymphoma (cHL) have traditionally been poor, in part, related to poor tolerance to standard chemotherapy. Herein, we evaluated the survival of patients with...
6.
Ansell S, Radford J, Connors J, Dlugosz-Danecka M, Kim W, Gallamini A, et al.
N Engl J Med
. 2022 Jul;
387(4):310-320.
PMID: 35830649
Background: Five-year follow-up in a trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma showed long-term progression-free survival benefits with first-line therapy with brentuximab vedotin, a...
7.
Chahal M, Hayden A, Savage K, Villa D, Scott D, Gerrie A, et al.
Leuk Lymphoma
. 2022 Jun;
63(11):2739-2742.
PMID: 35749607
No abstract available.
8.
Zhu K, Jamroz A, Huang S, Villa D, Freeman C, Scott D, et al.
Br J Haematol
. 2022 May;
198(4):684-692.
PMID: 35567407
Hodgkin variant Richter transformation (HvRT) is a rare and challenging complication of chronic lymphocytic leukaemia (CLL) for which information on prognostic factors and treatment approaches remain limited. We analysed characteristics...
9.
Lo A, Holloway C, Savage K, Sehn L, Worsley D, Connors J, et al.
Leuk Lymphoma
. 2022 May;
63(5):1242-1245.
PMID: 35514121
No abstract available.
10.
Takata K, Chong L, Ennishi D, Aoki T, Li M, Thakur A, et al.
J Clin Invest
. 2022 Apr;
132(10).
PMID: 35380993
PRAME is a prominent member of the cancer testis antigen family of proteins, which triggers autologous T cell-mediated immune responses. Integrative genomic analysis in diffuse large B cell lymphoma (DLBCL)...